No Data
No Data
Institutional Investors Are Roivant Sciences Ltd.'s (NASDAQ:ROIV) Biggest Bettors and Were Rewarded After Last Week's US$290m Market Cap Gain
Buy Rating Justified by Roivant Sciences' Strategic Positioning and Promising Drug Pipeline
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
Express News | Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Express News | Roivant Sciences Ltd - Topline Results Are Expected by End of Calendar Year 2024
Express News | Roivant and Kinevant Sciences Complete Enrollment in Resolve-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis